Preoperative combined hemoglobin, albumin, lymphocyte and platelet levels predict survival in patients with locally advanced colorectal cancer

// Huihong Jiang 1, * , Huaguang Li 2, * , Ajian Li 3 , Erjiang Tang 2 , Dan Xu 2 , Yin Chen 2 , Yong Zhang 3 , Min Tang 3 , Zhiyong Zhang 4 , Xiaxing Deng 1 , Moubin Lin 2, 3 1 Department of General Surgery, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China 2 Center for Translational Medicine, Yangpu Hospital Affiliated to Shanghai Tongji University School of Medicine, Shanghai, China 3 Department of General Surgery, Yangpu Hospital Affiliated to Shanghai Tongji University School of Medicine, Shanghai, China 4 Department of General Surgery, Zhuji People's Hospital of Zhejiang Province, Zhejiang, China * These authors have contributed equally to this work Correspondence to: Moubin Lin, email: lmbin@hotmail.com Xiaxing Deng, email: xiaxingdeng@126.com Keywords: colorectal cancer, HALP, prognostic, risk, survival Received: June 07, 2016      Accepted: September 16, 2016      Published: September 27, 2016 ABSTRACT More than 50% of patients with colorectal cancer (CRC) are initially diagnosed with locally advanced CRC (LACRC), and half of those patients develop recurrence or metastasis after resection. Here, we investigated whether the novel index HALP, which is a combination of preoperative hemoglobin, albumin, lymphocyte and platelet levels, correlates with survival in LACRC patients. A total of 820 patients with LACRC from two independent hospitals were included in our study. The correlations between HALP and overall and cancer-specific survival were calculated using training and validation sets. Lower HALP values correlated with an increased risk of death and cancer-related death in both sets. Moreover, the risk score based on HALP allowed stratification of patients into distinct prognostic groups with greater accuracy than previously proposed indexes. These results suggest that HALP may be useful as a clinical prognostic factor for patients with LACRC.